ADMA Biologics Inc (NASDAQ:ADMA)’s share price was up 6.5% during mid-day trading on Monday . The company traded as high as $4.89 and last traded at $4.77, approximately 753,000 shares were traded during mid-day trading. A decline of 17% from the average daily volume of 904,597 shares. The stock had previously closed at $4.48.
A number of equities research analysts recently issued reports on ADMA shares. BidaskClub upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Saturday. Dawson James cut ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Monday, August 12th. Maxim Group restated a “buy” rating and issued a $12.00 price objective on shares of ADMA Biologics in a research note on Tuesday, August 27th. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Oppenheimer set a $14.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. ADMA Biologics presently has a consensus rating of “Buy” and an average target price of $10.20.
The stock has a 50 day moving average of $4.61 and a 200-day moving average of $4.27. The firm has a market capitalization of $262.18 million, a P/E ratio of -3.29 and a beta of 2.71. The company has a debt-to-equity ratio of 1.79, a quick ratio of 7.93 and a current ratio of 10.26.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.04. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%. The business had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $4.36 million. As a group, sell-side analysts expect that ADMA Biologics Inc will post -0.95 EPS for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in ADMA. Perceptive Advisors LLC grew its holdings in shares of ADMA Biologics by 76.7% during the second quarter. Perceptive Advisors LLC now owns 11,521,102 shares of the biotechnology company’s stock worth $44,586,000 after purchasing an additional 5,000,000 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of ADMA Biologics by 25.1% during the second quarter. Jane Street Group LLC now owns 58,374 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 11,711 shares in the last quarter. Citadel Advisors LLC grew its holdings in shares of ADMA Biologics by 96.3% during the second quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 10,887 shares in the last quarter. Jefferies Group LLC purchased a new position in shares of ADMA Biologics during the second quarter worth about $2,961,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of ADMA Biologics during the second quarter worth about $1,128,000. Hedge funds and other institutional investors own 59.07% of the company’s stock.
ADMA Biologics Company Profile (NASDAQ:ADMA)
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Article: What is Compound Interest?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.